secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001437749-26-009298
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin enrolls 45th subject in MIRACLE AML trial; interim data unblinding on track for mid-2026
--------------------------------------------------------------------------------

- 45th subject enrolled in pivotal Phase 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML.
- Interim unblinding of first 45 subjects remains on track for mid-2026; CEO calls it potentially the most important data moment.
- Early blinded data among first 30 patients showed 40% composite complete remission rate (30% CR, 10% CR with partial hematologic recovery).
- Approximately 35% of subjects had previously failed venetoclax-based therapies; many had adverse genetic markers.
- Enrollment progressing toward 90-subject Part A completion expected in Q3 2026; Phase 3 design to follow dose determination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926009298/0001437749-26-009298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926009298/mbrx20260320_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-009298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer